Alan Bash

Chief Executive Officer at Zielbio, Inc.

52 year

Health Technology

Consumer Services

Profile

Alan S.
Bash is currently the Chief Executive Officer & Director at Zielbio, Inc. Prior to this, he was the President, Chief Executive Officer & Director at Checkmate Pharmaceuticals, Inc. in 2022.
He also worked as a Senior Vice President-Commercial Model Innovation at Bristol Myers Squibb Co. Mr. Bash completed his undergraduate degree at Georgetown University and earned an MBA from Columbia Business School.

Alan Bash active positions

Companies	Position	Start
Zielbio, Inc. Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.	Chief Executive Officer	2023-01-02

All active positions of Alan Bash

Former positions of Alan Bash

Companies	Position	End
BRISTOL-MYERS SQUIBB COMPANY	Corporate Officer/Principal	-
CHECKMATE PHARMACEUTICALS, INC.	Chief Executive Officer	-

See the detail of Alan Bash's experience

Training of Alan Bash

Georgetown University	Undergraduate Degree
Columbia Business School	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Alan Bash's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BRISTOL-MYERS SQUIBB COMPANY	Health Technology

Private companies	2
Checkmate Pharmaceuticals, Inc. Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.	Health Technology
Zielbio, Inc. Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.	Health Technology